SMAD4 and nasopharyngeal carcinoma: Indeed, Kaplan‐Meier survival analysis showed that NPC patients with mutations in TGFBR2 and SMAD4 tended to have poor local recurrence‐free survival (P = .037) as compared to patients without TGFBR2 and SMAD4 mutations (Figure 5E).